Stockscreener 앱 받기
7.46
1.45%
-0.11
전일 마감가:
$7.57
열려 있는:
$7.57
하루 거래량:
1.05M
Relative Volume:
2.16
시가총액:
$492.91M
수익:
-
순이익/손실:
$-44.47M
주가수익비율:
-7.3274
EPS:
-1.0181
순현금흐름:
$-33.50M
1주 성능:
+3.04%
1개월 성능:
-7.67%
6개월 성능:
+5.37%
1년 성능:
+20.52%
1일 변동 폭
$7.275
$7.70
1주일 범위
$7.07
$8.07
52주 변동 폭
$5.25
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.46 | 529.25M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 개시 | William Blair | Outperform |
| 2025-07-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 개시 | H.C. Wainwright | Buy |
| 2025-06-16 | 개시 | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 개시 | Craig Hallum | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
모두보기
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
How Is Eupraxia Pharmaceuticals (TSX:EPRX) Using Drug Delivery Technology To Target Inflammatory Diseases? - Kalkine Media
Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Durable EoE Data Strengthens Investor Optimism - kalkine.ca
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients - marketscreener.com
Eupraxia reports 52-week data from EoE treatment trial - Investing.com
Eupraxia Pharmaceuticals Posts Strong 52-Week EoE Data for EP-104GI in RESOLVE Trial - TipRanks
Fifty-two weeks after one dose, 9 of 14 patients with an esophageal disease remained in remission. - Stock Titan
Eupraxia Pharmaceuticals Stock Price Forecast. Should You Buy EPRX.TO? - StockInvest.us
Eupraxia Pharmaceuticals Price Target Announced at $17.00/Share by Wedbush - Moomoo
Why Eupraxia Pharmaceuticals (TSX:EPRX) Is the S&P/TSX SmallCap Biotech Investors Are Tracking - kalkine.ca
Eupraxia Pharmaceuticals (TSX:EPRX) Stock Slips 5.13%: RESOLVE Trial Execution, Diffusphere Formulation Pacing, and Pre-Commercial Valuation Scrutinized - kalkine.ca
Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating By Investing.com - Investing.com Canada
Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating - Investing.com India
Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target - Yahoo Finance
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - Eastern Progress
Eupraxia Pharmaceuticals Inc.(TSX: EPRX) added to S&P Global BMI Index - marketscreener.com
Eupraxia Pharmaceuticals at H.C. Wainwright conference: focus on durability By Investing.com - Investing.com Canada
WHY PMET Resources (TSX:PMET), Diversified Royalty (TSX:DIV), Eupraxia Pharmaceuticals (TSX:EPRX), Fireweed Metals (TSXV:FWZ) and Standard Lithium (TSXV:SLI) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Rises 5.51% as Clinical Momentum and Nasdaq Upgrade Support Investor Sentiment - kalkine.ca
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice - Yahoo Finance
Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - Kalkine
EPRX: Innovative annual therapy for EoE shows rapid, durable efficacy and strong commercial prospects - TradingView
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price Today: $8.07 - Gotrade
Eupraxia Pharmaceuticals Inc. (EPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences - Investing News Network
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach - TipRanks
Why Did Eupraxia Pharmaceuticals (TSX:EPRX) Surge 12.36% on 4 September 2026? - kalkine.ca
Pharma Eupraxia (Nasdaq: EPRX) moves to Nasdaq's top tier - Stock Titan
No shareholder action is needed as Eupraxia shares move to Nasdaq’s highest tier. - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
EPRX Stock Jumps As Traders Eye Volatile Breakout - timothysykes.com
EPRX Jumps As Traders Focus On Cash Runway And Momentum - StocksToTrade
Top 10 Best Biotech Companies In Canada 2026 - Nubia Magazine!
Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Clinical Progress Supports a More Constructive Investor Outlook - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Surges 9.56% Today as RESOLVE Trial Momentum and Major Q4 Catalyst Fuel Investor Optimism - kalkine.ca
Eupraxia Pharmaceuticals Stock Slides 3.34%: Can Clinical Momentum Offset Renewed Downside Pressure? - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Slides 3.34% as Clinical-Stage Risks and Biotech Volatility Pressure Sentiment - kalkine.ca
Eupraxia Pharmaceuticals Stock Falls 8.75% as Clinical-Stage Volatility Tests Investor Confidence Despite Pipeline Potential - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Faces Downside Pressure as Biotech Volatility and Clinical Execution Risks Weigh on Investor Sentiment - kalkine.ca
Could Eupraxia Pharmaceuticals (TSX:EPRX) Reach Its Next Milestone? - Kalkine Media
EUPRAXIA PHARMACEUTICALS INC. SEC Filing (Aug 25, 2026) - Stock Titan
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Gains Investor Momentum as Clinical Progress and Pipeline Advancement Strengthen Biotechnology Outlook - kalkine.ca
Could Eupraxia Pharmaceuticals (TSX:EPRX) Gain Fresh Market Attention? - Kalkine Media
Eupraxia (EPRX) Watch: Finishes 0.44% Lower at $6.73 in the Latest Reading; Technical View: $6.39 and $7.07 Define the Nearby Reference Levels under the Current SnapshotPut Call Ratio - vinanet.vn
Eupraxia Pharmaceuticals Stock Falls 4.12% as Investors Weigh Clinical Progress Against Biotech Development and Financing Risk - kalkine.ca
Eupraxia Slides as Biotech Traders Take Risk Off the Table — What Could Trigger the Next Move? - kalkine.ca
Eupraxia Pharmaceuticals Faces Fresh Downside Pressure as Clinical Execution Risk Clouds the EoE Story - kalkine.ca
Eupraxia (EPRX) Quarter in Focus: EPS Does Not Reach the Reported Estimate for This Review - vinanet.vn
Eupraxia Pharmaceuticals Market Sentiment - Benzinga France
Eupraxia (EPRX) Quarter in Focus: EPS Does Not Reach the Reported Estimate for This Review; Post-Report: Shares Fall 2.85% in the Available RecordFree Cash Flow Trends - dars.gov.et
What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday? - wealthawesome.com
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.32%
자본화:
|
볼륨(24시간):